MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways

Figure 1

Comparisons of ALP staining and activities between the control and IL-1β treatment groups (20 ng/ml, 10 ng/ml, 5 ng/ml, 2.5 ng/ml, and 1.25 ng/ml). (a) Osteoblasts were stained for ALP levels after being induced with the osteogenic differentiation medium for 7 days (upper lanes). Details of ALP staining at day 7 (lower lanes). (b) ALP activities were detected after cell induction for 7 days. Data are expressed as mean ± SD for n = 3.  < 0.05 versus the control group.

(a)

(b)